Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine

Sehui Kim
ORCID logo ,
Yeji Park
ORCID logo ,
Jeonghun Kim
,
Sohyun Kim
,
Kyungmin Choi
,
Taegyun Kang
,
Inho Lee
,
Yong Taik Lim
,
Soong Ho Um
,
Chul Kim
*
Version 1 : Received: 31 July 2023 / Approved: 31 July 2023 / Online: 1 August 2023 (10:13:40 CEST)

A peer-reviewed article of this Preprint also exists.

Kim, S.; Park, Y.; Kim, J.; Kim, S.; Choi, K.; Kang, T.; Lee, I.; Lim, Y.T.; Um, S.H.; Kim, C. ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine. Vaccines 2023, 11, 1503. Kim, S.; Park, Y.; Kim, J.; Kim, S.; Choi, K.; Kang, T.; Lee, I.; Lim, Y.T.; Um, S.H.; Kim, C. ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine. Vaccines 2023, 11, 1503.

Abstract

Despite numerous studies on cancer treatment, cancer remains a challenging disease to cure, even after decades of research. In recent years, cancer vaccine has emerged as a promising approach for cancer treatment, offering few unexpected side effects compared to existing therapies. How-ever, cancer vaccine faces obstacles to commercialization due to its low efficacy. Particularly, the Toll-like receptor (TLR) adjuvant system, specifically the TLR 7/8 agonist, has shown potential for activating Th1 immunity, which stimulates both innate and adaptive immune responses through T cells. In this study, we developed ProLNG-S, a cholesterol-conjugated form of resiquimod (R848), to enhance immune efficacy by stimulating the immune system and reducing toxicity. ProLNG-S was formulated as ProLNG-001, a positively charged liposome, and co-administered with oval-bumin (OVA) protein in the B16-OVA model. ProLNG-001 effectively targeted secondary lym-phoid organs, resulting in a robust systemic anti-tumor immune response and tumor-specific T cell activation. Consequently, ProLNG-001 demonstrated potential for preventing tumor progression and improving survival compared to AS01 by enhancing anti-tumor immunity.

Keywords

cancer vaccine; adjuvant; nanovaccines; TLR 7/8 agonist; melanoma; immunomodulator

Subject

Biology and Life Sciences, Biology and Biotechnology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.